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ORIGINAL ARTICLE
Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic
hand/foot eczema treated with azathioprine
F. M. Garritsena, J. van der Schafta, C. A. F. Bruijnzeel-Koomena, R. H. van Schaikb,c, M. de Graafa,
M. P. H. van den Broekd,e and M. S. de Bruin-Wellera
aDepartment of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands; bDepartment of Clinical Chemistry, Erasmus
University Medical Center Rotterdam, Rotterdam, The Netherlands; cLaboratory for Clinical Chemistry and Hematology (LKCH), University
Medical Center Utrecht, Utrecht, The Netherlands; dDepartment of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The
Netherlands; eDepartment of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands
ABSTRACT
Background: Azathioprine is frequently used in severe eczema. It is converted in the liver into active
metabolites, including 6-thioguanine nucleotide (6-TGN) and methylated 6-methylmercaptopurine
(6-MMP). In the past, the therapeutic potential of azathioprine may have not been fully utilized. Recent
investigations on inflammatory bowel disease have led to a better understanding of azathioprine metabol-
ism and optimizing treatment.
Objective: To investigate whether measuring thiopurine metabolites in circulation can improve the effect-
iveness and safety of azathioprine treatment in patients with atopic dermatitis and/or chronic hand/foot
eczema.
Methods: Azathioprine metabolite levels were measured in eczema patients during maintenance treat-
ment (Part I) and dose escalation (Part II). Clinical effectiveness, hepatotoxicity, and bone marrow suppres-
sion were analyzed and TPMT genotype was assessed.
Results: A wide variation in metabolite levels in all dose groups was observed. In Part I (32 patients),
there were no significant differences in 6-TGN levels between clinical responders and non-responders
(p¼ .806). No hepatoxicity or myelotoxicity was observed. In Part II, all 6-TGN and 6-MMP levels increased
during dose escalation. Hypermethylation was observed in 2/8 patients.
Conclusion: For individual eczema patients treated with azathioprine, routinely measuring 6-TGN and
6-MMP can be helpful in optimizing azathioprine dose, improving clinical effectiveness, and preventing
side effects.
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Atopic dermatitis (AD) and chronic hand/foot eczema are common
chronic inflammatory skin diseases. Although the majority of
patients can be treated adequately with topical corticosteroids
and/or phototherapy, oral immunosuppressive drugs are indicated
in more severe cases.
Azathioprine (AZA) is an important off-label drug in the man-
agement of severe and difficult to treat AD. Randomized clinical tri-
als report a decrease in clinical scores, varying from 26% to 37%
decrease in SASSAD (Six Area, Six Sign Atopic Dermatitis) score and
39% decrease in SCORAD (Scoring Atopic Dermatitis) score after
12weeks. The percentage of patients reporting adverse events in
these short-term (12weeks) randomized clinical trials ranged
between 5.6% and 22.9% (1). Abnormalities in cell count, such as
lymphocytopenia, were most frequently reported. In 9% of the
patients, these adverse events led to withdrawal and in 9% of
patients dose adjustments were made. However, in daily practice,
results are less favorable. In an AD population treated with AZA in
daily practice, Thomsen et al. found more than 30% treatment fail-
ure after one year of AZA treatment: 9/60 patients (15%) had to dis-
continue due to a lack of clinical benefit and 12/60 patients (20%)
due to side effects (2).
In a retrospective daily practice study in two university hospi-
tals in the Netherlands, also 30% (14/46) of the adult AD patients
treated with AZA discontinued treatment due to side effects and/
or ineffectiveness (3). In a recent drug survival study of 94 AD
patients treated with AZA in daily practice, 57% discontinued
treatment due to ineffectiveness (19%), side effects (36%), or both
(2%) (4).
Little data are available on the efficacy of AZA in chronic
hand/foot eczema. Agarwal et al. performed a randomized con-
trolled trial in which the use of AZA (n¼ 45) was compared to
topical clobetasol proprionate 0.05% (n¼ 46) in patients with
chronic hand eczema. After 24weeks of treatment, the improve-
ment of itch and the improvement of the HECSI (hand eczema
scoring index) were significantly higher in the AZA group
(p¼ .003 and p¼ .001, respectively) (5).
In the past, the therapeutic potential of AZA may has not been
fully utilized (6). The AZA metabolism is very complex due to the
involvement of various enzymes; it is studied thoroughly in
patients with inflammatory bowel disease (IBD). AZA is a thiopur-
ine pro-drug and has no immunosuppressive activity itself. In the
liver, AZA is converted into 6-mercaptopurine (6-MP).
Subsequently, 6-MP undergoes metabolic transformations, via a
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complex enzymatic pathway, resulting in a variety of pharmaco-
logically active metabolites (Figure 1) (7). The most important
metabolites are 6-thioguanine nucleotide (6-TGN) and methylated
6-methylmercaptopurine (6-MMP). The immunosuppressive effect
of AZA is caused by the 6-TGN metabolites. Intracellular 6-TGN is
incorporated into DNA instead of guanine nucleotides, which,
after a strand breakage, triggers cell-cycle arrest and apoptosis.
This results in the inhibition of nucleotide and protein synthesis,
and ultimately in the inhibition of lymphocyte proliferation (8–10).
However, the main mechanism of immunomodulation is by induc-
ing T-cell apoptosis by modulation cell (Rac1) signaling (11). The
therapeutic onset after thiopurine initiation is delayed as it takes
12–17weeks for TGNs to be incorporated into DNA (12,13). This
explains the delayed clinical efficacy in AD, which is usually
reached after 3–4months.
Recent investigations, especially in IBD, have led to a better
understanding of the AZA metabolism and optimization of treat-
ment (6,14,15). Therapeutic drug monitoring can reveal noncom-
pliance or under-dosing and can be used as a practical tool to
optimize AZA therapy (6). Data on the AZA metabolism and thera-
peutic drug monitoring of AZA metabolites in patients with
chronic inflammatory skin diseases are scarce. Recently, Reynolds
et al. suggested, based on their unpublished experience in individ-
ual patients with AD, that measuring 6-TGN levels particularly in
patients with heterozygote thiopurine S-methyltransferase (TPMT)
activity may be useful (16). The aim of the present study is to
investigate whether measurement of thiopurine metabolites is
helpful in improving effectiveness and safety of AZA treatment in
patients with AD and/or chronic hand/foot eczema.
Methods
Study population
This study was exempted from review by our institutional review
board. In this prospective mono-center study, AZA metabolite lev-
els were measured in adult patients with AD and/or hand/foot
eczema during maintenance treatment (100mg/day, for more
than three months) (Part I). The criteria of Hanifin and Rajka and
of Williams et al. were used for the diagnosis of AD (17,18). The
following patient characteristics were collected: age, sex, type of
eczema (AD or hand/foot eczema), AZA dose, and the concomi-
tant use of oral corticosteroids. Additionally, AZA metabolites
were measured structurally in another small group of patients
from start of AZA treatment and during dose escalation (Part II).
Measurements of AZA metabolites
6-TGN and 6-MMP levels in red blood cells (RBC) were measured
in erythrocytes, as a surrogate marker of the levels in leukocytes,
using the Dervieux-method (19). The majority of previously pub-
lished studies used the Lennard method (comparison of the val-
ues shown in Table 1).
Metabolites were analyzed by the Clinical Pharmaceutical and
Toxicological laboratory of the Department of Pharmacy,
University Medical Center Utrecht, The Netherlands.
Outcomes
Part I
6-TGN and 6-MMP steady-state levels were measured and ratios
between these metabolites were calculated in all patients. The
correlation between the AZA dose and the metabolite levels was
investigated.
6-TGN and 6-MMP levels and 6-MMP/6-TGN ratios between res-
ponders and non-responders were compared. Responsiveness was
based on the Investigator Global Assessment (IGA, 6-point scale)
(20). A responder was defined as IGA 0–2. Non-responders were
defined as an IGA 3–5 or concomitant treatment with oral cortico-
steroids. The optimal 6-TGN level to achieve disease control was
defined as the median 6-TGN level in the responder group.
TPMT genotype was determined. Safety results, including hep-
atotoxicity and bone marrow suppression, were analyzed.
Clinically significant hepatotoxicity was defined as an alanine ami-
notransferase (ALT) or aspartate aminotransferase (AST) two times
the upper limit of normal (ALT: >45U/L in men and >35U/L









Figure 1. Azathioprine metabolism (simplified). 6-MMP: methylated 6-methylmercaptopurine; 6-TGN: 6-thioguanine nucleotide; HGPRT: hypoxanthine-guanine
phosphoribosyl transferase; TPMT: thiopurinemethyltransferase; XO: xanthine oxidase.





6-TGN 230–450 600–1200 pmol/8 108 RBC
6-MMP/6-TGN ratio 5–25 2–10 pmol/8 108 RBC
Toxic
6-TGN >450 >1200 pmol/8 108 RBC
6-MMP >5700 >5700 pmol/8 108 RBC
Values used by the Dutch Society of Clinical Pharmarcy, based on studies
using Lennard method in inflammatory bowel disease patients and the conversion
factor 2.6 for deriving the Dervieux values (33).

























Bone marrow suppression was defined as white blood cell
count <4 109/L and/or thrombocytopenia (platelet count
<150 109/L).
Part II
AZA metabolites were measured in a small group of patients from
the start of treatment and during dose escalation. Patients started
with AZA 50mg/day, followed by metabolite measurement after
2weeks (T1). TPMT genotype was determined using TaqMan ana-
lysis. When hepatotoxicity or bone marrow suppression was not
observed, AZA dose was increased to 100mg/day, followed by
metabolite measurement 2weeks later (T2). Finally, the dose was
increased to 150mg/day, again followed by metabolite measure-
ment 2weeks later (T3).
The following patient characteristics were collected in these
patients: age, sex, type of eczema (AD or hand/foot eczema), 6-
TGN, and 6-MMP levels at T1, T2, and T3.
Because the therapeutic effect after AZA initiation is delayed
up to four months, clinical efficacy was not evaluated at this early
time point.
Statistical analysis
The data of the total group were evaluated. Subgroup analyzes
for responders and non-responders were made. All statistical ana-
lyzes were performed using SPSS version 21.0 (IBM Corp., Armonk,
NY; 2012). Frequencies, percentages, and medians with inter quar-
tile ranges (IQR) were calculated.
The Mann–Whitney U test and the Chi Square test were used
to calculate whether there were statistically significant differences
between responders and non-responders, regarding sex, age,
dose, 6-TGN levels, and 6-MMP levels. The ANOVA test, corrected
for multiple testing by Bonferroni, was used to calculate whether
there were statistically significant differences in 6-TGN and 6-MMP




Thirty-five patients were treated with AZA. Three patients (8.6%)
had 6-TGN levels <50 pmol/8 108 RBC and 6-MMP levels
<250 pmol/8 108 RBC, suggesting noncompliance to AZA. These
patients were excluded from further analysis: 32 patients remained
for further analysis (Table 2).
The median age at metabolite measurement was 48.0 years
[IQR 43.0–56.7]. Twenty-three patients (71.9%) had the diagnosis
AD. The other nine patients had isolated hand- and/or foot-
eczema (eight dyshidrotic eczema, one hyperkeratotic eczema).
Twenty-four patients (75.0%) used monotherapy AZA (dose range
100–200mg/day). Eight patients (25.0%) used concomitant oral
corticosteroids (dose range 5–30mg/day)
Metabolite levels
AZA dose varied from 100 to 200mg/day with a median dose of
150mg/day [IQR 100.0–187.5] (Figure 2).
Twenty-eight patients had an extensive metabolizer TPMT
genotype, three patients had an intermediate metabolizer TPMT
genotype (1/3A). In one patient the TPMT genotype determin-
ation failed.
There was a wide variation in metabolite levels in all dose
groups. 6-TGN levels varied between 42 and 696pmol/8 108 RBC
in patients using 100mg/day, between 99 and 656 pmol/8 108
RBC in patients using 150mg/day and between 142 and
861 pmol/8 108 RBC in patients using 200mg/day. 6-MMP levels
varied between 205 and 3411 pmol/8 x108 RBC in patients using
100mg/day, between 275 and 26,027 pmol/8 108 RBC in patients
using 150mg/day, and between 126 and 4173 pmol/8 108 RBC
in patients using 200mg/day. In six (18.8%) patients (all using
150mg/day) the 6-MMP level was >5700 pmol/8 108 RBC (toxic
level). The steady state 6-MMP/6-TGN ratio varied from 0.9 to 81.2
in patients using 100mg/day, from 1.2 to 262.9 in patients using
150mg/day, and from 0.5 to 18.9 in patients using 200mg/day.
The metabolite levels of the three TPMT1/3A patients are high-
lighted in Figures 2 and 3.
6-MMP levels were statistically significantly different among
patients with various AZA doses (p¼ .0431), but not after correc-
tion for body weight (data not shown). 6-TGN levels were signifi-
cantly higher in the three patients with an intermediate
metabolizer TPMT genotype (p¼ .01) compared to patients with
an extensive metabolizer TPMT genotype, but no 6-TGN levels
above the upper limit of 1200 were observed.
Responders versus non-responders
In total, 16 patients were characterized as responder and 16
patients as non-responder (Table 3, Figure 3).
Responders were significantly older (median 50.9 years versus
44.3 years in the non-responder group) at the time of the metab-
olite measurement (p¼ .029). There were no significant differences
in AZA dose (mg/day) (p¼ .628), 6-TGN levels (p¼ .806), 6-MMP
levels (p¼ .763), or 6-MMP/6-TGN ratios (p¼ .940) between res-
ponders and non-responders.
The median 6-TGN level in the responder group was
197.0 pmol/8 108 RBC.
Safety
No patient met the criteria of hepatotoxicity. Six patients had 6-
MMP levels >5700 pmol/8 108 RBC (toxic level, Table 3) with a
median duration of treatment until metabolite measurement of
0.82 years [IQR 0.27–2.16]. Two of these patients (al extensive
metabolizer TPMT genotype) had slightly increased ALT levels at
time of metabolite measurement (83U/L in one male patient and
42U/L in one female patient).
None of the 32 patients met the criteria of bone marrow
depression. None of the patients had 6-TGN levels >1200 pmol/
8 108 RBC (toxic level, Table 3).
Part II. AZA metabolites were measured consecutively in eight
patients (three men, five women) from start of AZA treatment and
during dose escalation (Table 4, Figure 4). Median age at start of
AZA treatment was 46.2 years [39.9–50.9]. Five patients were diag-
nosed with AD, three patients with isolated hand/foot eczema.
Seven patients had an extensive metabolizer TPMT genotype. The
TPMT genotype was missing in one patient. 6-TGN and 6-MMP
values at the different measurements varied widely. All levels of 6-
TGN and 6-MMP increased during dose escalation up to T3
Table 2. Patient characteristics (Part I).
All patients (n¼ 32)
Male, n (%) 15 (46.9)
Age at AZA metabolite measurement (years),
median [IQR]
48.0 [43.0–56.7]
Patients with AD, n (%) 23 (71.9)
Patients with isolated hand/foot eczema, n (%) 9 (28.1)
AZA dose in mg/day, median [IQR] 150.0 [100.0–187.5]
Concomitant use of oral corticosteroids, n (%) 8 (25.0)
AD: atopic dermatitis; AZA: azathioprine; IQR: inter quartile range.

























(150mg/day). In one patient (patient 5), AZA dose was not
increased to 150mg/day due to subjective side effects.
Thiopurine hypermethylation (low 6-TGN with high 6-MMP)
was observed in patients 2 and 3.
Discussion
This study aimed to investigate whether measurement of thiopur-
ine metabolites is helpful in improving effectiveness and safety of
AZA treatment in patients with AD and/or chronic hand/foot
eczema.
A wide inter- and intra-individual variation in both 6-TGN and
6-MMP levels in patients with AD or chronic hand/foot eczema
during AZA maintenance treatment was observed. Metabolite lev-
els between individuals were not significantly related to the AZA
dose, but within individuals higher AZA dose led to higher metab-
olite levels. Metabolite levels were not significantly different
between responders and non-responders.
Several past studies investigated thiopurine metabolites and
their relation to clinical efficacy and side effects in IBD. Although
it is hypothesized that 6-TGN is responsible for the immunosup-
pressive effect of AZA, several studies in IBD patients failed to find
a statistically significant correlation between metabolite levels,
and clinical response (6,22–25).
A prospective study of steroid-dependent patients with IBD
showed that dose optimization of AZA to achieve 6-TGN levels
250 pmol/8 108 RBC was significantly associated with a higher
rate of disease remission (Lennard method) (26).
Other studies in IBD suggest a therapeutic range in 6-TGN con-
centration between 235 and 490pmol/8 108 RBC (Lennard
method) as significantly more exacerbations were found in
patients below the threshold of 235 pmol/8 108 (6,27–29). The
risk for leucocytopenia increased with 6-TGN levels above
490 pmol/8 108 RBC (6,29,30).
6-TGN and 6-MMP levels are not routinely measured during
AZA treatment in dermatological diseases. However, attempts
have been made in a small number of studies to optimize clinical
efficacy of AZA by measuring metabolite levels. Recently,
Reynolds et al. suggested, based on their unpublished experience
in individual cases, that measuring 6-TGN levels particularly in
patients with heterozygote TPMT activity may be useful (16).
In 2009, el Azhary et al. investigated the optimal levels of
6-TGN for disease remission in patients with immunobullous dis-
ease treated with AZA (Dervieux method). They found a mean
optimal level of 6-TGN of 190.7 pmol/8 108 RBCs (31). Limited
disease (involving only the oral or genital mucosa, the face, or lim-
ited areas on the chest) was found to require less 6-TGN to
achieve clinical improvement in their study, with a mean of
145.3 pmol/8 108 RBCs.
In 2013, Caufield et al. reported on a case series of 12 children
with recalcitrant AD treated with AZA (32). They found in 11 res-
ponders, 6-TGN levels ranging from 45 to 358pmol/8 108 RBC
Figure 3. Responders versus non-responders and steady-state metabolite levels (Part I) (median with IQR). ¼ Intermediate metabolizer TPMT genotype. A, 6-TGN
level; B, 6-MMP level. There was no significant difference in 6-TGN levels (p¼ .806) and 6-MMP levels (p¼ .763) between responders and non-responders. 6-MMP:
methylated 6-methylmercaptopurine; 6-TGN: 6-thioguanine nucleotide; IQR: inter quartile range; RBC: red blood cell.
Figure 2. Azathioprine dose (100, 150, and 200mg/day) and steady-state metabolite (6-TGN and 6-MMP) levels (Part I) (median with IQR). ¼ Intermediate metabol-
izer TPMT genotype. A, azathioprine dose (mg/day) and 6-TGN level; B, azathioprine dose (mg/day) and 6-MMP level. 6-MMP levels were statistically significantly differ-
ent among patients with various AZA dose (p¼ .0431); 6-TGN levels were not significantly different among patients with different AZA dose (p¼ .0682). 6-MMP:
methylated 6-methylmercaptopurine; 6-TGN: 6-thioguanine nucleotide; IQR: inter quartile range; RBC: red blood cell.

























during stable disease (not clear whether the Dervieux or Lennard
method was used).
The above mentioned studies on AZA treatment in dermato-
logical disease and our results (showing a median 6-TGN level in
responders 197.0), suggest that 6-TGN levels needed to induce
clinical efficacy might be lower compared to IBD. Though, differ-
ences in measurement methods (Dervieux versus Lennard) may
have contributed to these differences as well, because some stud-
ies using Dervieux methods in IBD patients also reported lower
6-TGN levels for therapeutic response (33).
The majority of the non-responders in our study had low
6-TGN levels compared to responders (Figure 2), but this differ-
ence was not significantly different. This may be a consequence of
the small sample size and the large variation in 6-TGN levels in
the responders. Dose escalation was not performed in the non-
responder group for a number of reasons, such as subjective side
effects and the potential risk of hepatotoxicity.
Literature on the use of AZA in IBD patients reports an
increased risk for hepatotoxicity in case of 6-MMP levels higher
than 5700 pmol/8 108 RBC. In the present study, none of the
patients met the criteria of hepatotoxicity, though high 6-MMP
levels (>5700 pmol/8 108 RBC) were found in 6/32 patients (two
clinical responders and four non-responders). These patients may
be at risk of developing hepatotoxicity when AZA is continued for
longer periods.
The metabolism of AZA is partly influenced by genetic poly-
morphisms in thiopurine S-methyltransferase (TPMT). This results
in inter-individual variation in the metabolism of thiopurines; both
with respect to side effects and efficacy (13). High TPMT activity is
associated with lower 6-TGN levels and high 6-MMP levels, which
may result in decreased immunosuppressive activity and an
increased risk of hepatotoxicity. Patients with high TPMT activity
may be underdosed with standard AZA dose, which could explain,
at least partially, non-responsiveness to AZA. Increasing daily AZA
dose in these patients will not lead to higher effectiveness
because of a preferential 6-MMP production.
TPMT activity is not the only predictor for the risk of hepato-
toxicity. Other metabolites, other enzymatic conversions within
the metabolic pathway or interference medication (like aminosali-
cylates, non-steroidal anti-inflammatory drugs, anticoagulant, diu-
retics, and infliximab) may also influence the production of 6-MMP
metabolites (34). Furthermore, low TPMT activity is associated
with high 6-TGN levels, resulting in an increased risk of myelotox-
icity. However, TPMT activity does not predict myelotoxicity in all
patients. Therefore, monitoring haematological parameters
remains crucial (35). Reports indicate that between 50% and 75%
of thiopurine-related leucopenia occurs in patients with normal
TPMT activity (13,36,37). Finally, although TPMT activity is gener-
ally measured only once before starting therapy, some studies
have shown that TPMT levels are not static and induction of activ-
ity can occur during treatment (31,32). Therefore measurement of
6-TGN and 6-MMP instead of TPMT activity seems to be more rele-
vant to predict/monitor the risk of hepato- and myelotoxicity. In
this study, information on TPMT genotype was missing in two
patients (one in Part I and one in Part II). Since these patients dis-
played normal complete blood counts and AZA metabolite levels,
the TPMT genotype in these patients was assumed to be normal.
Recent studies on AZA in IBD and AD have reported high per-
centages of treatment failure due to sides effects and/or inefficacy
(2,3,4,38). We suggest that this may, at least partly, be related to a
skewed thiopurine metabolism profile. The so-called
‘ultramethylators’ (hypermethylators) preferentially produce exces-
sive amounts of 6-MMP, whereas 6-TGN levels remain very low
(6-MMP/6-TGN range above 20) (38,39,40). We observed this phe-
nomenon in both parts of this study. In part I of this study, 6/32
patients (18.8%), all using AZA 150mg/day, had high 6-MMP levels
(>5700 pmol/8 108 RBC). Three of them had 6-TGN levels
<235 pmol/8 108 RBC, suggesting thiopurine hypermethylation
or preferential 6-MMP production. In Part II of this study, thiopur-
ine hypermethylation was observed in patients 2 and 3 (25%).
These hypermethylators are at risk of side effects and non-respon-
siveness, resulting in AZA discontinuation after several months of
treatment. TPMT activity does not predict the risk of hypermethy-
lation. Thus, metabolite levels should be routinely monitored from
start of treatment and during dose escalation in order to detect
hypermethylators early in AZA treatment.
Studies in IBD patients showed that concomitant use of allo-
purinol can result in a shift of the AZA metabolism towards the
production of 6-TGN, reducing the relative formation of 6-MMP
(41–44).
Three patients were excluded because they had 6-TGN
levels <50 pmol/8 108 RBC and 6-MMP levels <250 pmol/8 108
RBC, indicating that they had not been taking their medication.
The (suspected) noncompliance rate was 8.5%. One patient con-
firmed noncompliance; in the other two patients compliance
remained unclear. One of these two patients still had an active
eczema; the other was in clinical remission. It should be taken
into consideration that low 6-TGN and 6-MMP levels may be a
Table 3 Responders versus non-responders (Part I).
Responders (n¼ 16) Non-responders (n¼ 16) p value
Male, n (%) 7 (43.8) 8 (50) .723
Age at AZA metabolite measurement (years), median [IQR] 50.9 [46.7–61.3] 44.3 [26.0–52.1] .029
AZA dose (mg/day), median [IQR] 150.0 [100.0–187.5] 150.0 [112.5–187.5] .628
Steady-state 6-TGN level (pmol/8 108 RBC), median [IQR] 197.0 [110.3–619.5] 219.0 [167.3–281.3] .806
Number of patients with 6-TGN levels >1200, n (%) 0 (0.0) 0 (0.0) –
Steady-state 6-MMP level (pmol/8x108 RBC), median [IQR] 2324.0 [829.8–3228.5] 2156.5 [668.3–6982.5] .763
Number of patients with 6-MMP levels >5700, n (%) 2 (12.5) 4 (25.0) .365
Steady-state 6-MMP/6-TGN ratio, median [IQR] 5.6 [3.2–27.7] 7.0 [3.2–25.5] .940
AZA: azathioprine; 6-MMP: methylated 6-methylmercaptopurine; 6-TGN: 6-thioguanine nucleotide; IQR: inter quartile range.
Table 4 6-TGN and 6-MMP levels in eight patients during dose escalation
(Part II).
All patients (n¼ 8)
Male, n (%) 3 (37.5)
Patients with AD, n (%) 5 (62.5)
Patients with isolated hand/foot eczema, n (%) 3 (37.5)
6-TGN level (pmol/8 108 RBC), median [IQR]
T1 (2 weeks, 50mg/day) 70.0 [50.3–91.8]
T2 (4 weeks, 100mg/day) 170.0 [130.5–193.3]
T3a (6 weeks, 150mg/day) 262.5 [164.5–359.3]
6-MMP level (pmol/8 108 RBC), median [IQR]
T1 (2 weeks, 50mg/day) 284.0 [250.0–301.3]
T2 (4 weeks, 100mg/day) 788.5 [393.5–1154.5]
T3a (6 weeks, 150mg/day) 1384.0 [932.5–3253.3]
aIn one patient, dose was 125mg/day due to subjective side effects.
AZA: azathioprine; 6-MMP: methylated 6-methylmercaptopurine; 6-TGN:
6-thioguanine nucleotide; IQR: inter quartile range.

























Figure 4. 6-TGN and 6-MMP levels in patients treated with AZA treatment during dose escalation.

























result of noncompliance; however, a patient-dependent variation
in the AZA metabolism (e.g. malabsorption, yet unknown enzyme
defects or extremely high enzyme activity in the thiopurine path-
way) cannot be excluded (6).
Limitations
Concomitant medication (including aminosalicylates, non-steroidal
anti-inflammatory drugs, anticoagulants, diuretics, and infliximab)
may interfere with the thiopurine metabolism, but in this study
no information on concomitant medication (except for oral corti-
costeroids) was collected (34).
In order to use a clinical parameter that was useful in both AD
and chronic hand/foot eczema, the IGA was selected to define
response to treatment. This clinical score is less detailed than for
instance the EASI (Eczema Area and Severity Index) score that is
commonly used as a score for AD severity.
Conclusion
For individual AD patients treated with AZA, routinely measuring
6-TGN and 6-MMP levels can be helpful in optimizing AZA dose,
improving clinical effectiveness, and preventing side effects.
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